About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
ASPC 2020 Virtual Summit on CVD Prevention
Videos
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
J
Primary Prevention by CAC vs. CTA: Which One Is Better and Why? - SCCT Expert Debate
By
ASPC 2020 Virtual Summit on CVD Prevention
FEATURING
James Min
,
Khurram Nasir
By
ASPC 2020 Virtual Summit on CVD Prevention
FEATURING
James Min
,
Khurram Nasir
36 views
March 16, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
18:06
Lilly Obesity
Getting Patients Started with an Obesity Treatment Option for Adults
Feat.
E. Lazarus
Featured Video
18:06
Lilly Obesity
Getting Patients Started with an Obesity Treatment Option for Adults
Feat.
E. Lazarus
Videos
35:56
ASPC 2020 Virtual Summit on CVD Prevention
Integrating Imaging & Advanced Blood Testing for CVD Prevention/…
Feat.
A. Agatston
08:09
ASPC 2020 Virtual Summit on CVD Prevention
Implementation of FIND FH Into Clinical Care at Penn Medicine: Can M…
Feat.
S. Sheth
05:37
ASPC 2020 Virtual Summit on CVD Prevention
Lessons Learned from the ISCHEMIA Trial: How to Diagnose/Manage CAD …
Feat.
D. Maron
11:29
ASPC 2020 Virtual Summit on CVD Prevention
Managing Patients With Stable CAD: When to Consider the Cath Lab? Wh…
Feat.
D. Maron
21:16
ASPC 2020 Virtual Summit on CVD Prevention
ASPC Expert Discussion on Biologics Usage for CV Risk Reduction, Eff…
Feat.
C. Ballantyne,
A. Marie Navar,
D. Maron,
K. Ferdinand,
P. Ridker
07:35
ASPC 2020 Virtual Summit on CVD Prevention
Continuity of Care for Patients With/At High Risk for CVD During COV…
Feat.
A. Khera
08:31
ASPC 2020 Virtual Summit on CVD Prevention
Management of HF With Preserved Ejection Fraction: How Can We Preven…
Feat.
D. Schocken
18:46
ASPC 2020 Virtual Summit on CVD Prevention
How Can We Prevent the Majority of CV Events? What Are the Milion He…
Feat.
L. Sperling
19:17
ASPC 2020 Virtual Summit on CVD Prevention
NIH Scientific Approach to Inclusive Excellence: Why Diversity Matte…
Feat.
H. A. Valantine
10:53
ASPC 2020 Virtual Summit on CVD Prevention
ASPC CVD Prevention Panel Discussion: How Can We Educate Our Patient…
Feat.
L. Shaw,
N. Wenger,
V. Taqueti,
R. Bullock-Palmer,
E. Michos,
M. Gulati,
P. Taub
05:07
ASPC 2020 Virtual Summit on CVD Prevention
Expert Discussion on Transdermal Hormone Replacement Therapy & H…
Feat.
L. Shaw,
N. Wenger,
V. Taqueti,
R. Bullock-Palmer,
E. Michos,
M. Gulati,
P. Taub
12:41
ASPC 2020 Virtual Summit on CVD Prevention
Disparities in the Use of Preventive Medications and Risk Factor Con…
Feat.
K. Vu
27:57
ASPC 2020 Virtual Summit on CVD Prevention
100 Years from C-Reactive Protein to Anti-Inflammatory Therapy for A…
Feat.
P. Ridker
28:45
ASPC 2020 Virtual Summit on CVD Prevention
Apolipoprotein B & CVD Risk: How Can We Improve CVD Prevention W…
Feat.
A. Sniderman
32:07
ASPC 2020 Virtual Summit on CVD Prevention
Adverse Pregnancy Outcomes & CVD Risk: What Are the Risks and Ho…
Feat.
R. Bullock-Palmer
07:13
ASPC 2020 Virtual Summit on CVD Prevention
FH Visual Aids in Patient Education Research Highlights: Can Distrib…
Feat.
D. M. Harmon
05:51
ASPC 2020 Virtual Summit on CVD Prevention
HF With Preserved Ejection Fraction: How to Distinguish HFrEF & …
Feat.
D. Schocken
15:01
ASPC 2020 Virtual Summit on CVD Prevention
Diagnosis/Management of CMD: How to Use Novel Imaging Tools to Under…
Feat.
V. Taqueti
27:34
ASPC 2020 Virtual Summit on CVD Prevention
Atherosclerosis & MicroRNAs: How MicroRNAs Impacts Risk for Athe…
Feat.
P. Toth
37:24
ASPC 2020 Virtual Summit on CVD Prevention
Primary Prevention by CAC vs. CTA: Which One Is Better and Why? - SC…
Feat.
J. Min,
K. Nasir
47:06
ASPC 2020 Virtual Summit on CVD Prevention
Jackson Heart Study Overview: Racial Disparity Trends, Risk Assessme…
Feat.
H. Taylor
19:28
ASPC 2020 Virtual Summit on CVD Prevention
ASPC Panel Discussion on CV Risk Prevention With Nutrition, Hyperten…
Feat.
K. Ferdinand,
D. Maron,
L. Sperling,
I. Pina,
H. Taylor
20:21
ASPC 2020 Virtual Summit on CVD Prevention
Discussion on CTA/CAC for Primary Prevention, Genetic Testing, LDL M…
Feat.
R. Blankstein,
S. Virani,
A. Agatston,
J. Min,
S. Sheth,
K. Nasir,
A. Khera
28:23
ASPC 2020 Virtual Summit on CVD Prevention
New Insights Into Assessing Risk for Hispanic Patients: Why it Is Im…
Feat.
I. Pina
16:33
ASPC 2020 Virtual Summit on CVD Prevention
Menopause and Its Impact on Women's CVD Health: How to Assess R…
Feat.
E. Michos
14:00
ASPC 2020 Virtual Summit on CVD Prevention
Genetic Testing in Preventive Cardiology: Are Those With FH Mutation…
Feat.
A. Khera
14:55
ASPC 2020 Virtual Summit on CVD Prevention
Statin Usage in Athletes: Is There Increased Muscle Injury With Stat…
Feat.
P. D. Thompson
27:36
ASPC 2020 Virtual Summit on CVD Prevention
Sex Differences in Atherosclerosis: Is There a Sex Specific Phenotyp…
Feat.
L. Shaw
16:05
ASPC 2020 Virtual Summit on CVD Prevention
Polypill for CVD Prevention: When Is Polypharmacy Appropriate? Can R…
Feat.
K. Ferdinand
28:02
ASPC 2020 Virtual Summit on CVD Prevention
CVD Prevention for Women: What Are the Unique/Predominant Risk Facto…
Feat.
N. Wenger
